InvestorsHub Logo
Followers 8
Posts 2018
Boards Moderated 0
Alias Born 07/19/2006

Re: gr8db8 post# 1123

Tuesday, 08/15/2017 1:09:33 AM

Tuesday, August 15, 2017 1:09:33 AM

Post# of 2099
I think you're right. At the end of the day, if VB111/Avastin shows a 30 day benefit in prolonging life in patients with no options, it will be approved(especially under current FDA stewardship). If VB111 also shows a tail of longer term survivors... i.e. over 18 months, this will strengthen their case. If the survival benefit is less than a month, probably not. The central issue is if the trial shows a survival benefit for patients who received VB111. Fingers crossed for VB111.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News